CC's Q3 Earnings Miss Estimates on Weak TSS Volumes

Chemours’ Q3 2026 adjusted EPS was $0.21, missing the $0.26 consensus by 19.2%; sales rose 3% year over year to $1.54 billion, while adjusted EBITDA increased 6% to $200 million. TSS revenue fell 9% and segment adjusted EBITDA declined 30%, offset partly by stronger TT pricing and a 240% increase in TT adjusted EBITDA. Chemours forecast Q4 sales down 5–10% sequentially and FY2026 adjusted EBITDA of $775–$800 million; net leverage was about 4.3 as of September 30, with the company targeting below 4.2 by year-end.

Analysis

CC: earnings quality and leverage matter more than the headline miss

The key risk is that reported cash generation overstates the underlying deleveraging capacity: Q3 operating cash flow included a large PFAS insurance receipt, while free cash flow fell year over year despite that support. With net leverage still elevated, any shortfall against the year-end reduction target would keep credit risk and equity sensitivity to operating volatility in focus. Verify cash flow excluding exceptional receipts and payments before crediting the target.

The earnings mix is also fragile. TT’s pricing recovery is helping offset TSS weakness, but it is not yet clear whether pricing can persist if soft demand in China and EMEA broadens or volumes fail to follow. TSS’s lower North American aftermarket volumes may partly reflect a difficult comparison, not lost share; do not treat one quarter as proof that competitors are taking business. Conversely, persistent weakness after seasonal normalization would make the margin decline more concerning.

Near term, Q4 seasonality and the guided EBITDA range cap the case for a quick rebound; the immediate debate is whether the FY outlook is achievable, not whether adjusted EPS missed by itself. Over 1–3 months, watch actual segment EBITDA, TT price realization versus volume, and net leverage. Over 6–18 months, sustained pricing and cash conversion could repair the balance-sheet narrative, while renewed refrigerant weakness or weaker TiO2 demand would undermine it. The contrarian point: the earnings miss may be less important than the market’s potential underweighting of cash-flow quality. Still, a short is not compelling without valuation, bond-spread, and options-implied-volatility context.

Key Decisions for Investors

• Keep CC underweight pending evidence that operating cash flow converts to debt reduction without relying on exceptional receipts; verify the year-end net-leverage outcome against the stated target.
• Do not chase TT’s pricing-driven improvement. Track realized pricing alongside volumes, especially in China and EMEA; weakening volume alongside any price giveback would falsify the margin-recovery thesis.
• Treat TSS weakness as a watch item rather than a confirmed share-loss thesis. Reassess after seasonal demand normalizes; persistent volume and margin deterioration would strengthen the downside case.
• No immediate options or pair trade: first check CC valuation, credit spreads, and implied volatility. A defined-risk bearish position is only worth evaluating if guidance is cut or leverage progress stalls, rather than on the EPS miss alone.
• Do not use RS, ESI, or ASM as direct hedges for CC: the supplied information does not establish sufficiently matched business or factor exposure.